ES2591252T3 - Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional - Google Patents
Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional Download PDFInfo
- Publication number
- ES2591252T3 ES2591252T3 ES03768289.5T ES03768289T ES2591252T3 ES 2591252 T3 ES2591252 T3 ES 2591252T3 ES 03768289 T ES03768289 T ES 03768289T ES 2591252 T3 ES2591252 T3 ES 2591252T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- keto
- dihydro
- irritable bowel
- test substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000006549 dyspepsia Diseases 0.000 title claims abstract description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 12
- 150000003180 prostaglandins Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 21
- -1 prostaglandin compound Chemical class 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract description 4
- 239000000126 substance Substances 0.000 description 28
- 206010000059 abdominal discomfort Diseases 0.000 description 25
- 239000000902 placebo Substances 0.000 description 24
- 229940068196 placebo Drugs 0.000 description 24
- 238000011282 treatment Methods 0.000 description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 description 13
- 235000021152 breakfast Nutrition 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010062745 Chloride Channels Proteins 0.000 description 10
- 102000011045 Chloride Channels Human genes 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000008030 elimination Effects 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 229960000711 alprostadil Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 108010043769 CLC-2 Chloride Channels Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000020560 abdominal swelling Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 101000605172 Aspergillus niger (strain CBS 513.88 / FGSC A1513) Probable endopolygalacturonase E Proteins 0.000 description 2
- 101000605171 Aspergillus niger Endopolygalacturonase E Proteins 0.000 description 2
- 101000941281 Bos taurus Gastric triacylglycerol lipase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 2
- 229940127558 rescue medication Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DZUXGQBLFALXCR-BMPPNWMBSA-N 7-[(1R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)\C=C\C1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-BMPPNWMBSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100023509 Chloride channel protein 2 Human genes 0.000 description 1
- 101710091667 Chloride channel protein 2 Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101150020741 Hpgds gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 101150080623 PGB gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710191567 Probable endopolygalacturonase C Proteins 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- QLPYHQHJKMTHED-BUHFOSPRSA-N methyl 7-[3-hydroxy-2-[(e)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCCC(O)\C=C\C1C(O)CC(=O)C1CCCCCCC(=O)OC QLPYHQHJKMTHED-BUHFOSPRSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- QLPYHQHJKMTHED-UHFFFAOYSA-N prostaglandin E1 methyl ester Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(=O)OC QLPYHQHJKMTHED-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43646202P | 2002-12-27 | 2002-12-27 | |
| US43646302P | 2002-12-27 | 2002-12-27 | |
| US436463P | 2002-12-27 | ||
| US436462P | 2002-12-27 | ||
| PCT/JP2003/016857 WO2004060377A1 (en) | 2002-12-27 | 2003-12-26 | Derivatives of prostaglandins for treating abdominal discomfort |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2591252T3 true ES2591252T3 (es) | 2016-11-25 |
Family
ID=32717850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03768289.5T Expired - Lifetime ES2591252T3 (es) | 2002-12-27 | 2003-12-26 | Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7795312B2 (enExample) |
| EP (2) | EP2281564A3 (enExample) |
| JP (2) | JP4889219B2 (enExample) |
| KR (2) | KR20120045051A (enExample) |
| CN (1) | CN1753680B (enExample) |
| AR (1) | AR042670A1 (enExample) |
| AU (1) | AU2003292556B2 (enExample) |
| BR (1) | BRPI0317740B8 (enExample) |
| CA (1) | CA2510051C (enExample) |
| ES (1) | ES2591252T3 (enExample) |
| MX (1) | MXPA05006981A (enExample) |
| NO (1) | NO335441B1 (enExample) |
| NZ (1) | NZ541110A (enExample) |
| TW (1) | TWI336254B (enExample) |
| WO (1) | WO2004060377A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI331920B (en) | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
| EP1562604B1 (en) * | 2002-10-23 | 2012-01-04 | Sucampo AG | Prostaglandin compounds for the treatment of obesity |
| US8337891B2 (en) * | 2003-07-03 | 2012-12-25 | Sucampo Ag | Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
| TWI387454B (zh) | 2004-09-02 | 2013-03-01 | 蘇坎波公司 | 治療胃腸道疾病之方法及組成物 |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| CN101180096B (zh) * | 2005-03-21 | 2015-04-22 | 苏坎波公司 | 用于治疗粘膜疾病的方法和组合物 |
| EP1871380B1 (en) * | 2005-04-12 | 2011-10-19 | Sucampo AG | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders |
| US7868045B2 (en) | 2006-09-06 | 2011-01-11 | Sucampo Ag | Method for promoting gastrointestinal bicarbonate secretion |
| JP2010519177A (ja) * | 2007-02-27 | 2010-06-03 | スキャンポ・アーゲー | ミトコンドリアを保護するための組成物および方法 |
| US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
| US20090030072A1 (en) | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
| JP5797655B2 (ja) * | 2009-09-18 | 2015-10-21 | アドラー・コーポレーション | 消化管障害のためのオピオイド受容体アンタゴニストの使用 |
| IT1402047B1 (it) * | 2010-10-19 | 2013-08-28 | Cross Pharma Sa | Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013161973A1 (en) * | 2012-04-23 | 2013-10-31 | Sucampo Ag | Method for treating irritable bowel syndrome with diarrhea |
| CN105102432B (zh) | 2012-10-15 | 2019-01-04 | Epizyme股份有限公司 | 经取代的苯化合物 |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1581886A (en) * | 1977-05-26 | 1980-12-31 | May & Baker Ltd | Prostanol derivatives |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| JPH0681728B2 (ja) * | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
| US5317032A (en) * | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| TW224942B (enExample) | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
| EP0455448B1 (en) * | 1990-05-01 | 1998-12-09 | R-Tech Ueno Ltd. | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| US6242485B1 (en) | 1996-06-10 | 2001-06-05 | R-Tech Ueno | Endothelin antagonist |
| US6046239A (en) * | 1997-08-05 | 2000-04-04 | American Home Products Corporation | Anthranilic acid analogs |
| EP0978284B1 (en) * | 1997-11-28 | 2008-07-23 | Sucampo AG | Use of 15-keto-prostaglandin-e compounds as endothelin antagonists |
| US6492417B1 (en) * | 1997-12-22 | 2002-12-10 | Alcon Manufacturing, Ltd. | 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists |
| DE60039727D1 (de) * | 1999-10-15 | 2008-09-11 | Sucampo Ag | Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid |
| JP4183943B2 (ja) * | 2000-04-06 | 2008-11-19 | スキャンポ・アーゲー | １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物 |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| AR035242A1 (es) * | 2001-05-18 | 2004-05-05 | Sucampo Ag | Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado |
| AU2002330747B2 (en) | 2001-08-31 | 2007-07-19 | Sucampo Ag | Prostaglandin analogs as chloride channel opener |
| TWI331920B (en) * | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
| US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
-
2003
- 2003-12-26 AU AU2003292556A patent/AU2003292556B2/en not_active Expired
- 2003-12-26 KR KR1020127006692A patent/KR20120045051A/ko not_active Ceased
- 2003-12-26 JP JP2004564537A patent/JP4889219B2/ja not_active Expired - Lifetime
- 2003-12-26 NZ NZ541110A patent/NZ541110A/en not_active IP Right Cessation
- 2003-12-26 CA CA2510051A patent/CA2510051C/en not_active Expired - Lifetime
- 2003-12-26 EP EP10177588A patent/EP2281564A3/en not_active Withdrawn
- 2003-12-26 WO PCT/JP2003/016857 patent/WO2004060377A1/en not_active Ceased
- 2003-12-26 MX MXPA05006981A patent/MXPA05006981A/es active IP Right Grant
- 2003-12-26 ES ES03768289.5T patent/ES2591252T3/es not_active Expired - Lifetime
- 2003-12-26 CN CN2003801099014A patent/CN1753680B/zh not_active Expired - Lifetime
- 2003-12-26 TW TW092136988A patent/TWI336254B/zh not_active IP Right Cessation
- 2003-12-26 KR KR1020057012162A patent/KR101164838B1/ko not_active Expired - Lifetime
- 2003-12-26 EP EP03768289.5A patent/EP1575596B1/en not_active Expired - Lifetime
- 2003-12-26 BR BRPI0317740A patent/BRPI0317740B8/pt not_active IP Right Cessation
- 2003-12-29 AR ARP030104848A patent/AR042670A1/es not_active Application Discontinuation
- 2003-12-29 US US10/745,689 patent/US7795312B2/en not_active Expired - Lifetime
-
2005
- 2005-07-26 NO NO20053623A patent/NO335441B1/no not_active IP Right Cessation
-
2010
- 2010-08-02 US US12/848,597 patent/US20100298424A1/en not_active Abandoned
-
2011
- 2011-11-01 JP JP2011240314A patent/JP2012031202A/ja active Pending
-
2013
- 2013-03-18 US US13/845,353 patent/US20130217770A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0317740B8 (pt) | 2021-05-25 |
| EP2281564A2 (en) | 2011-02-09 |
| WO2004060377A1 (en) | 2004-07-22 |
| NO335441B1 (no) | 2014-12-15 |
| BR0317740A (pt) | 2005-11-22 |
| EP2281564A3 (en) | 2012-09-05 |
| EP1575596B1 (en) | 2016-06-22 |
| CN1753680A (zh) | 2006-03-29 |
| US20100298424A1 (en) | 2010-11-25 |
| KR20120045051A (ko) | 2012-05-08 |
| US20130217770A1 (en) | 2013-08-22 |
| CA2510051C (en) | 2016-07-05 |
| JP4889219B2 (ja) | 2012-03-07 |
| US20040138308A1 (en) | 2004-07-15 |
| MXPA05006981A (es) | 2005-12-14 |
| JP2012031202A (ja) | 2012-02-16 |
| TW200418491A (en) | 2004-10-01 |
| AR042670A1 (es) | 2005-06-29 |
| KR101164838B1 (ko) | 2012-07-11 |
| EP1575596A1 (en) | 2005-09-21 |
| CN1753680B (zh) | 2010-12-08 |
| AU2003292556B2 (en) | 2009-09-10 |
| BRPI0317740B1 (pt) | 2018-09-18 |
| NO20053623D0 (no) | 2005-07-26 |
| TWI336254B (en) | 2011-01-21 |
| JP2006513232A (ja) | 2006-04-20 |
| NZ541110A (en) | 2008-11-28 |
| NO20053623L (no) | 2005-09-26 |
| CA2510051A1 (en) | 2004-07-22 |
| AU2003292556A1 (en) | 2004-07-29 |
| US7795312B2 (en) | 2010-09-14 |
| KR20050086950A (ko) | 2005-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2296786T3 (es) | Composicion catartica. | |
| US20100298424A1 (en) | Method for treating abdominal discomfort | |
| EP2175861B1 (en) | Pharmaceutical combination of naproxen with 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1 | |
| ES2282408T3 (es) | 15-ceto-prostaglandina para el tratamiento de estreñimiento por farmaco. | |
| ES2368729T3 (es) | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento. | |
| JP5427029B2 (ja) | 消化管の重炭酸分泌を促進するための方法および組成物 | |
| JP2587441B2 (ja) | 製薬学的組成物 | |
| ES2603381T3 (es) | Derivados de prostaglandinas para tratar el estreñimiento | |
| EP3737378A1 (en) | Palonosetron for the treatment or prevention of nausea and vomiting | |
| TWI594751B (zh) | 治療帶有腹瀉之腸躁症之方法 | |
| NO20023463L (no) | Anvendelse av rofleponid i behandling av irritabelt tarmsyndrom (IBS) | |
| WO2004022045A1 (ja) | 下腹部及び／又は会陰部の疼痛改善剤 |